All Patients, n = 20 | IL-17A+, n = 9 | IL-17A−, n = 10 | |
---|---|---|---|
Mean age, yrs (range) | 60.7 (35–80) | 59.6 (35–74) | 61.5 (36–80) |
Male: female | 6:14 | 3:6 | 2:8 |
RF positive, n (%) | 18 (90) | 8 (88.9) | 9 (90) |
Radiographic erosions, n (%) | 19 (95) | 8 (88.9) | 10 (100) |
Disease duration, yrs, mean (range) | 16.9 (2–30) | 16.1 (5–29) | 19.2 (8–30) |
ESR, mm/h, mean (range) | 30 (0–85) | 21 (0–31) | 39 (18–85) |
CRP, mg/l, mean (range) | 11 (0–70) | 6.7 (0–26) | 8 (0–38) |
DMARD, n (%) | 18 (90) | 8 (88.9) | 8 (80) |
Methotrexate, n (%) | 10 (50) | 5 (55.5) | 4 (40) |
Methotrexate dose mg/wk, mean (range) | 16 (10–22.5) | 18 (15–22.5) | 14.1 (10–17.5) |
Prednisone | 12 | 5 | 6 |
Prednisone dose mg/day, mean (range) | 6 (4–10) | 6.5 (4–10) | 6 (5–10) |
RF: rheumatoid factor; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DMARD: disease modifying antirheumatic drugs.